HOME2020-11-26T19:17:43+00:00

The PD-MitoQUANT Project

Today, more than one million people live with Parkinson’s in Europe and this number is forecast to double by 2030. New, more effective treatments are urgently needed – but researchers and companies developing new drugs need to know more about how mitochondrial dysfunction is involved in disease progression and better models are needed for drug discovery and development.

PD-MitoQUANT is an Innovative Medicines Initiative (IMI) project that brings together academic experts, SMEs, pharmaceutical companies from the European Federation of Pharmaceutical Industries and Associations (EFPIA) and patient advocacy organisation Parkinson’s UK to:

  • improve our understanding of mitochondrial dysfunction in Parkinson’s,

  • identify and validate molecular drivers and mechanisms in Parkinson’s, and

  • discover innovative therapeutic targets that can be further progressed by the EFPIA partners in the future.

Meet our Researchers
Learn More about the Project
Check out our Publications
Browse our Newsletters

Latest News

RCSI STEM careers promotion talks present PD-MitoQUANT to young people

November 26th, 2020|

Midlands Science partnered with Dr Helena Bonner, a Neuroscientist at the Royal College of Surgeons in Ireland, as well as an Outreach officer at the Centre for Systems Medicine, RCSI to provide informative virtual talks for a number of schools across the Midlands for College Awareness Week.  Dr Helena Bonner [...]

PD-MitoQUANT Coordinator Prof Prehn participates in Neuronet roundtable at Alzheimer Europe Conference

October 27th, 2020|

Prof Jochen Prehn RCSI On Thursday afternoon, October 22, 2020, PD-MitoQUANT Coordinator Prof Jochen Prehn, of the RCSI participated in a Neuronet roundtable session titled: “Public-private partnerships in the post-COVID era” at the Alzheimer Europe Conference 2020. The international online conference was themed “Dementia in a changing world.”  [...]

Read more of our News
Go to Top